This Article Abstract Full Text (PDF) All Versions of this Article: 110/15/2246    most recent 01.CIR.0000144470.55149.E5v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tankó, L. B. Articles by Larsen, P. J. Search for Related Content PubMed PubMed Citation Articles by Tankó, L. B. Articles by Larsen, P. J. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB ESTRADIOL Genetics Home Reference Medline Plus Health Information Obesity Related Collections Obesity Pathophysiology Risk Factors Peripheral vascular disease Glucose intolerance Epidemiology

(Circulation. 2004;110:2246-2252.)
© 2004 American Heart Association, Inc.

Vascular Medicine

Novel Associations Between Bioavailable Estradiol and Adipokines in Elderly Women With Different Phenotypes of Obesity

Implications for Atherogenesis

László B. Tankó, MD, PhD; Jens M. Bruun, MD, PhD; Peter Alexandersen, MD; Yu Z. Bagger, MD; Bjørn Richelsen, MD; Claus Christiansen, MD; Philip J. Larsen, MD, PhD

From the Prospective Epidemiological Risk Factor (PERF) study group, Center for Clinical and Basic Research, Ballerup, Denmark (L.B.T., P.A., Y.Z.B., C.C.); the Department of Endocrinology and Metabolism C, Århus Amtssygehus, Århus University, Århus, Denmark (J.M.B., B.R.); and Rheoscience, Rødovre, Denmark (P.J.L.).

Correspondence to Dr László B. Tankó, Center for Clinical and Basic Research, Ballerup byvej 222, 2750 Ballerup, Denmark. E-mail lbt{at}ccbr.dk

Received June 18, 2004; revision received August 1, 2004; accepted August 4, 2004.

	Abstract

Top Abstract Introduction Methods Results Discussion References

 
Background— Peripheral adiposity confers protection against diabetes and atherosclerosis in elderly women. The underlying mechanisms, however, remain to be elucidated.

Methods and Results— On the basis on dual-energy X-ray absorptiometry measurements of central fat mass (CFM) and peripheral fat mass (PFM), we identified 290 elderly women with distinct forms of body fat distribution (lean, peripheral obesity, central obesity, or general obesity). Study parameters were plasma tumor necrosis factor-, interleukin (IL)-6, adiponectin, estradiol, sex hormone–binding globulin, insulin resistance, and aortic calcification, graded on lateral radiography. In peripherally and generally obese women, plasma estradiol and insulin resistance were significantly lower, whereas sex hormone–binding globulin and adiponectin were significantly higher compared with centrally obese women independent of age, body mass index, total fat mass, and smoking habits (all P<0.05). After adjustment for these confounders, IL-6 in centrally obese women was comparable with that seen in generally obese (similar high CFM%) but significantly higher than in peripherally obese women and lean women (low CFM%). Atherosclerosis was less severe in generally obese (2.5±0.3) compared with centrally obese women (5.0±0.7, P=0.001). In multiple regression analysis, total fat mass, body fat distribution, insulin resistance, estradiol, current smoking, treated hyperlipidemia, and treated hypertension contributed independently to the variation of aortic calcification (R=0.55, SEE=3.60, P<0.001).

Conclusions— Abundant presence of PFM in generally obese women is associated with increased plasma adiponectin and higher insulin sensitivity, which could explain the apparent protection against the atherogenic effects of IL-6 derived from CFM. Low peripheral exposure to estradiol appears to be a sine qua non of maintained adiponectin secretion from PFM.

Key Words: obesity • insulin • atherosclerosis • hormones • aging

	Introduction

Top Abstract Introduction Methods Results Discussion References

 
The insulin resistance (IR) syndrome is an established risk factor for macrovascular disease and type 2 diabetes, two of the most significant health problems among the elderly (>65 years).^1,2 In the past decade, there has been a marked increase in the prevalence of obesity in women, which draws attention to the need for better understanding the implications for cardiovascular health.³ In elderly women, atherogenic effects of obesity is mainly a function of body fat distribution rather than body mass index (BMI) per se. The abundant presence of peripheral fat mass (PFM) appears to counteract the diabetogenic/atherogenic trends of central fat mass (CFM) through mechanisms involving insulin sensitization.^4–6 Mediators of this protective association, however, remain poorly understood.

Adipose tissue secretes a variety of bioactive substances, which can modulate IR and atherogenesis. Insulin resistance and accelerated atherogenesis in centrally obese women are associated with increased plasma levels of proinflammatory cytokines (interleukin [IL]-6 and tumor necrosis factor [TNF]-) and decreased plasma levels of the antiinflammatory adipokine adiponectin.⁷ However, mechanisms by which PFM counteracts the unfavorable balance of proinflammatory and antiinflammatory adipokines have not been systematically investigated. Given the established insulin-sensitizing, antiinflammatory, and antiatherogenic effects of adiponectin in animals,⁸ a constitutive contribution to the circulating adiponectin pool might explain the protective effects of PFM.

Observations on pregnant animals and women have pointed out that increased/prolonged exposure of body fat mass to estradiol may promote IR, involving inhibition of adiponectin.^9–11 Women with low sex hormone–binding globulin (SHBG) are at particularly increased risk for gestational diabetes,¹² which also points to the role of increased peripheral exposure to sex steroids. After menopause, adipocytes are primary sources of endogenous estrogens in women. Women with upper-body obesity have lower plasma SHBG and higher estradiol compared with women with lower-body obesity,¹³ the latter finding suggesting regional differences in the enzymatic conversion of steroid hormones in visceral versus subcutaneous adipocytes.^14–16 Potential influence of body fat distribution on estrogen metabolism and depot-specific secretion of adipokines with direct consequences for IR and atherogenesis has received moderate attention.

Therefore, the aim of the study was to analyze (1) the independent associations between fat distribution and circulating levels of fat-derived hormones/adipokines and (2) whether phenotype-specific patterns of these hormones can explain the association of body fat distribution with IR and aortic calcification (AC) in elderly women.

	Methods

Top Abstract Introduction Methods Results Discussion References

 
Participants were 290 healthy women, 60 to 85 years of age, who were selected from a large cohort to obtain groups with distinct body fat distribution. Methods of selection have been described and illustrated earlier in detail.⁴ Briefly, CFM (sum of subcutaneous and visceral fat mass of the trunk) and PFM (fat mass of legs and arms) of all 1356 subjects were measured by dual-energy X-ray absorptiometry (DEXA) (Hologic QDR4500). Fat depots were expressed as percentage of total body soft tissue mass and were scored on a scale from 1 to 4 (1, <25th; 2, 25 to 50th; 3, 50 to 75th; and 4, >75th percentile). Scores could be combined in 4x4 ways, of which 1 to 1 indicated lean women; 1 to 4, women with peripheral obesity; 4 to 1, women with central obesity; and 4 to 4, women with general obesity (Figure 1 in Reference ⁴). Twelve women with ongoing hormone replacement therapy were excluded from further analyses. All participants signed an approved consent form, and the study was carried out in accordance with the Helsinki Declaration II. The local ethics committee approved the study protocol.

Traditional cardiovascular factors collected were BMI, blood pressure, level of education, smoking habits, daily coffee consumption, regular alcohol consumption, weekly fitness activities, presence of treated diabetes mellitus, treated hypertension, and treated hyperlipidemia. Insulin resistance was estimated by the homeostasis model assessment of insulin resistance (HOMA_IR) index (fasting insulin [µU/mL] x fasting glucose [mmol/L])/22.5). Calcified deposits in the lumbar aorta were visualized on lateral radiographs and graded from 0 to 24, as described earlier in detail.⁴ All plasma analyses were performed in samples from fasting subjects. Adiponectin was measured with high-sensitive radioimmunoassay (Linco), whereas IL-6 and TNF- were measured with ELISA (R&D). Total plasma 17ß-estradiol and SHBG were measured by the Roche Elecsys 2010 immunoassay analyzer (Roche Diagnostics), using the recently introduced Elecsys-Estradiol II (detection limit, 18.4 pmol/L; intra-assay CV, 3.6%) and Elecsys-SHBG assays (detection limit, 0.35 nmol/L; intra-assay CV, 2.6%). Measured total estradiol divided by SHBG (free estradiol index, FEI) estimated the bioavailable pool.

Statistical Analysis
Results shown are mean±SEM unless otherwise indicated. Statistical analysis was performed with the use of SPSS software, version 11.01. Characteristics of the four phenotypes were compared by means of ANOVA or the Kruskal-Wallis test. General linear models compared the means of fat-derived hormones/adipokines, SHBG, HOMA_IR, and AC after adjustment for confounders (age, BMI, total fat mass [TFM], and smoking). A forced-entry model of multiple regression analysis, including a dummy variable adjusting for the four groups of body fat distribution, identified independent contributors to the variation of AC. Associations and differences were statistically different at a level of P<0.05.

	Results

Top Abstract Introduction Methods Results Discussion References

 
Cardiovascular Profile
Characteristics of the four groups of women with different phenotypes of obesity are summarized in Table 1. There were statistically significant differences between the four groups in terms of body size (BMI) and overall obesity (TFM), which were inversely associated with the frequency of current smoking and the overall duration of smoking.

View this table: [in this window] [in a new window]   TABLE 1. Cardiovascular Risk Profile of Study Participants

Body Fat Distribution
Lean women (low CFM%) and centrally obese women (high CFM%) had comparable low PFM%, whereas peripherally obese women (low CFM%) and generally obese (high CFM%) women had comparable high PFM% (Figure 1).

View larger version (14K): [in this window] [in a new window]   Figure 1. Relative presence of CFM and PFM fat mass in women with different phenotypes of obesity.

Independent Impact of Body Fat Distribution
Means of HOMA_IR and AC in women with different forms of body fat distribution before and after adjustment for potential confounders (age, smoking, BMI, and TFM) are shown in Figure 2. Under both conditions, peripherally and generally obese women showed significantly lower IR compared with centrally obese women. When comparing AC, the significantly lower AC scores of generally obese women compared with lean women and centrally obese women were no longer present after adjustment for overall obesity. Instead, centrally and generally obese women showed significantly higher AC scores compared with women with peripheral obesity and lean women.

View larger version (18K): [in this window] [in a new window]   Figure 2. Associations of body fat distribution with insulin resistance and AC in elderly women. Black and white bars indicate mean±SEM obtained before and after adjustment for age, BMI, total fat mass, and smoking, respectively. *P<0.05; a, versus lean women; b, versus peripherally obese women; c, versus centrally obese women; d, versus generally obese women.

Figure 3 indicates the means of the different adipokines/cytokines before and after adjustment for the same confounders. Under both conditions, the comparison of CFM%-matched groups revealed significantly higher plasma adiponectin in women with high compared with those with low PFM%. The highest adiponectin concentrations were apparent in peripherally obese women, whereas the lowest concentrations were observed in centrally obese women. IL-6 in centrally and generally obese women was comparable, especially after adjustment for overall obesity, whereas lean women and peripherally obese women displayed significantly lower plasma IL-6. Plasma TNF- did not show significant differences between the four groups.

View larger version (18K): [in this window] [in a new window]   Figure 3. Association of body fat distribution with adipokines/cytokines in elderly women. Black and white bars indicate mean±SEM obtained before and after adjustment for age, BMI, total fat mass, and smoking, respectively. *P<0.05; a, versus lean women; b, versus peripherally obese women; c, versus centrally obese women; d, versus generally obese women.

Figure 4 indicates means of estradiol, SHBG, and bioavailable estradiol before and after adjustment for age, smoking, BMI, and TFM. Lean and peripherally obese women were not different in terms of plasma estradiol despite significant differences in PFM%. In contrast, the higher CFM% in centrally obese women compared with lean women was accompanied with significantly increased estradiol. Interestingly, when adjusting for TFM, general obese women had significantly lower estradiol compared with centrally obese women despite comparable CFM%. Plasma SHBG was the lowest in centrally obese women, whereas peripherally and generally obese women had comparable high levels of the transport protein. Accordingly, peripherally and generally obese women had the lowest bioavailable estradiol followed by lean women and centrally obese women.

View larger version (18K): [in this window] [in a new window]   Figure 4. Association of body fat distribution with estradiol, SHBG, and bioavailable estradiol. Black and white bars indicate mean±SEM obtained before and after adjustment for age, BMI, total fat mass, and smoking, respectively. *P<0.05; a, versus lean women; b, versus peripherally obese women; c, versus centrally obese women; d, versus generally obese women.

Independent Contributors to IR and AC
In multiple regression analysis including the HOMA_IR index as dependent variable and independent variables outlined in Table 2, only adiponectin emerged as an independent contributor (ß=–0.243, P=0.001) to the variation of the HOMA_IR index (R=0.48, SEM =2.47, P<0.001). When changing the dependent variable to AC, the independent direct correlates of AC were body fat distribution, insulin resistance, current smoking, estradiol, treated hyperlipidemia, and treated hypertension, whereas total body fat mass was an independent inverse correlate of AC (Table 2).

View this table: [in this window] [in a new window]   TABLE 2. Independent Contributors to Variation of Aortic Calcification

Insulin Resistance and Atherosclerosis Adjusted for the Proposed Mediators
Means of IR and AC obtained after adjustment for confounders and the hypothesized mediators (bioavailable estradiol, IL-6, and adiponectin) of the described associations are shown in Figure 5. After these adjustments, no significant differences between the four groups were apparent.

View larger version (15K): [in this window] [in a new window]   Figure 5. Insulin resistance and AC in women with different forms of body fat distribution after adjustment for age, smoking, BMI (confounders), bioavailable estradiol, IL-6, and adiponectin (mediators).

	Discussion

Top Abstract Introduction Methods Results Discussion References

 
Comparison of women with distinct forms of body fat distribution provided a unique setting for investigating associations of body fat distribution with fat-derived hormones, IR, and AC. The striking findings were the better insulin sensitivity and less severe atherosclerosis of generally obese women compared with centrally obese women despite more pronounced overall and comparable CFM% in the former group. The question to be answered was whether constitutive contribution of subcutaneous adipocytes to circulating adiponectin—which has insulin-sensitizing, antiinflammatory, and antiatherogenic effects⁹—could underlie the protective associations of PFM.

Centrally obese women had lower adiponectin compared with lean women, illustrating the adverse impact of visceral adiposity on circulating adiponectin. However, generally obese women compared with centrally obese women had higher plasma adiponectin, which appears to be in line with the constitutive contribution of PFM. In further support, subcutaneous adipocytes (both abdominal and gluteal) of nondiabetic obese subjects were shown to have maintained high adiponectin expression/secretion compared with the low expression/secretion of visceral adipocytes.^17,18 In diabetic subjects, adiponectin expression/secretion of subcutaneous adipocytes is also low,¹⁸ suggesting that hormonal milieu characteristics for insulin-resistant/centrally obese subjects may inhibit adiponectin in both fat depots.

Hormonal changes characteristic for centrally obese women versus generally and peripherally obese women included markedly decreased SHBG and increased estradiol levels. The comparable high SHBG of generally and peripherally obese women suggests that signals from PFM stimulate hepatic SHBG release, a notion recently raised by Ducluzeau et al¹⁹ However, high PFM% is also prone to lower plasma estradiol, which could be explained, at least in part, by a contrasting impact of obesity on the 17ß-hydroxysteroid dehydrogenase (17ß-HSD)/aromatase ratio in visceral (increased ratio) and peripheral adipocytes (decreased ratio).¹⁶ High ratio promotes estradiol formation, whereas low ratio facilitates peripheral aromatization and formation of estrone, a 12-fold weaker form of estrogen.¹³ Thus, even though estradiol formation is expected to be increased in the visceral compartment of both centrally and generally obese women, the higher PFM% in the latter group appears to decrease the circulating pool either by converting or metabolizing estradiol.

Results of the study suggest that estradiol production and bioavailability have important implications for circulating adiponectin and whole-body IR. In support of this, (1) high plasma levels of bioavailable estradiol predict IR independent of the degree of overall and central adiposity,²⁰ (2) adiponectin is independently and inversely associated with plasma estradiol (but not with bioavailable testosterone),²¹ (3) increasing plasma estradiol in the course of pregnancy is associated with decreasing adiponectin and increasing IR, particularly in women with low SHBG, and these alterations ameliorate after delivery,^9–12,22 and (4) in mice, ovariectomy increases plasma adiponectin, which can be reversed by estradiol replacement.⁹ These observations provide strong support for the role of endogenous estradiol in the modulation of adiponectin secretion and IR.

Insulin, especially when administered with insulin sensitizers, is a potent stimulator of the adiponectin gene.²³ Similar to the reported differences in adiponectin expression^17,18 and estradiol formation,^14,16 insulin responsiveness also appears to be different between subcutaneous and visceral adipocytes of nondiabetic obese subjects; the latter showing decreased responsiveness attributable to reduced insulin receptor autophosphorylation and reduced expression and tyrosine phosphorylation of insulin receptor substrate 1 (IRS-1).²⁴ Prolonged exposure of adipocytes to increased plasma estradiol, for example, during pregnancy²⁵ or in women with central obesity,^26,27 appears to be to prone to decreased IRS-1 expression. Indeed, experimental studies confirm that the impact of estradiol on IRS-1 expression in adipocytes is dose and time dependent.²⁸ Low IRS-1 expression of subcutaneous adipocytes has been recently proposed as a marker of IR, low adiponectin expression/secretion, and accelerated atherogenesis.²⁷ Because centrally obese women in the present study had similarly high IR, low adiponectin, and signs of accelerated atherogenesis, it is tempting to postulate that the decreased expression of IRS-1 in subcutaneous adipocytes could reflect increased cellular exposure to estradiol. The apparent independent contribution of estradiol to the variation of AC found by the present study also points in this direction.

Generally and centrally obese women revealed comparably high levels of IL-6, indicating that contribution of fat mass to circulating IL-6 is mainly from the central compartment, with minor additional contribution from the peripheral compartment.^29,30 The contribution of adipocytes to circulating TNF- is minimal,³¹ yet this adipokine is known to be a potent autocrine regulator of IL-6 secretion in adipocytes.³² In centrally obese subjects with IR, expression of both proinflammatory adipokines is increased, which might also reflect the increased exposure of adipocytes to estradiol. The high interstitial concentration of IL-6 and its ability to decrease the expression of IRS-1 and the adiponectin gene suggest that this adipokine might be a mediator of the apparent adverse effects of estradiol on adipocytes.^33,34 Ultimate answers, however, demand in situ studies measuring the reactive changes in the cellular expression and interstitial concentration of adipokines in visceral fat in response to pharmacological inhibitors of estradiol formation.

Although plasma IL-6 was comparable in generally and centrally obese women, the severity of AC was markedly different, pointing to the importance of other factors. The significantly higher bioavailable estradiol and lower adiponectin of centrally compared with generally obese women nurtures the hypothesis that prolonged and increased exposure of subcutaneous adipocytes to estradiol may eliminate the protective contribution of PFM to circulating adiponectin, under which conditions the dominant presence of IL-6 may promote accelerated atherogenesis. The atherogenic effects of IL-6 are conferred mainly through stimulation of the release of C-reactive protein from hepatic and vascular cells and induction of IR in the liver and the skeletal muscle. The recent observation that these latter organs are primary sites of adiponectin receptors provides hints to why atherogenesis in postmenopausal women is a critical function of the relative presence of proinflammatory and antiinflammatory adipokines. Elimination of the differences in HOMA_IR and AC between the four groups by adjustment for bioavailable estradiol, IL-6, and adiponectin further nurtures the notion that these factors represent key mechanisms of IR and atherogenesis in elderly women.

Some methodological limitations deserve mentioning. DEXA is not able to provide direct measures of visceral fat mass, but comparative studies have demonstrated that it provides a good alternative to computer tomography for predicting visceral fat in elderly women (r=0.79 to 0.90).^35,36 Nevertheless, the present study cannot give definite answers to the contribution of the subcutaneous and the visceral compartment in the trunk region. Although the few available human studies comparing the expression and secretion of adipokines (IL-6 and adiponectin)^17,18,30 in adipocytes from well-defined compartments have provided useful hints, much remains to be elucidated pertaining to the regional differences in the function of adipose tissue in elderly women.

In summary, the novel associations of the present study provide reasons to believe that endogenous estradiol metabolism, which appears to be a function of body fat distribution, has important implications for adipokine secretion from adipocytes with direct implications for whole-body IR, inflammation, and atherogenesis in postmenopausal women. Because this study focused on the putative role of endogenous estradiol, future research should clarify whether central obesity has any implication for increased susceptibility to the adverse cardiovascular effects of hormone replacement therapy in diabetic patients early after initiation of the therapy (<1 year).³⁷

	Acknowledgments

 
Disclosure

Dr Christiansen is CEO of the Center for Clinical and Basic Research, an organization that performs clinical phase II and III and postmarketing trials for the pharmaceutical industry and that has worked with many sponsors that have been involved in the area of osteoporosis and postmenopausal complaints. He is a major shareholder in this company and a member of the board.

	References

Top Abstract Introduction Methods Results Discussion References

 
1. Raji A, Plutzky J. IR, diabetes, and atherosclerosis: thiazolidinediones as therapeutic interventions. Curr Cardiol Rep. 2002; 4: 514–521.[Medline] [Order article via Infotrieve]

2. Grant RW, Meigs JB. Should the IR syndrome be treated in the elderly? Drugs Aging. 2004; 21: 141–151.[CrossRef][Medline] [Order article via Infotrieve]

3. Steinbaum SR. The metabolic syndrome: an emerging health epidemic in women. Prog Cardiovasc Dis. 2004; 46: 321–336.[CrossRef][Medline] [Order article via Infotrieve]

4. Tankó LB, Bagger YZ, Alexandersen P, et al. Peripheral fat mass exhibits an independent dominant antiatherosclerotic effect in elderly women. Circulation. 2003; 107: 1626–1631.[Abstract/Free Full Text]

5. Tankó LB, Bagger YZ, Alexandersen P, et al. Central and peripheral fat mass have contrasting effect on the progression of aortic calcification in postmenopausal women. Eur Heart J. 2003; 24: 1531–1537.[Abstract/Free Full Text]

6. Snijder MB, Dekker JM, Visser M, et al. Associations of hip and thigh circumferences independent of waist circumference with the incidence of type 2 diabetes: the Hoorn Study. Am J Clin Nutr. 2003; 77: 1192–1197.[Abstract/Free Full Text]

7. Aldhahi W, Hamdy O. Adipokines, inflammation, and the endothelium in diabetes. Curr Diabetes Rep. 2003; 3: 293–298.[CrossRef]

8. Matsuzawa Y, Funahashi T, Kihara S, et al. Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol. 2004; 24: 29–33.[Abstract/Free Full Text]

9. Combs TP, Berg AH, Rajala MW, et al. Sexual differentiation, pregnancy, calorie restriction, and aging affect the adipocyte-specific secretory protein adiponectin. Diabetes. 2003; 52: 268–276.[Abstract/Free Full Text]

10. Retnakaran R, Hanley AJ, Raif N, et al. Reduced adiponectin concentration in women with gestational diabetes: potential factor in progression to type 2 diabetes. Diabetes Care. 2004; 27: 799–800.[Free Full Text]

11. Ranheim T, Haugen F, Staff AC, et al. Adiponectin is reduced in gestational diabetes mellitus in normal weight women. Acta Obstet Gynecol Scand. 2004; 83: 341–347.[CrossRef][Medline] [Order article via Infotrieve]

12. Kopp HP, Festa A, Krugluger W, et al. Low levels of sex-hormone–binding globulin predict insulin requirement in patients with gestational diabetes mellitus. Exp Clin Endocrinol Diabetes. 2001; 109: 365–369.[CrossRef][Medline] [Order article via Infotrieve]

13. Kirschner MA, Samojlik E. Sex hormone metabolism in upper and lower body obesity. Int J Obes. 1991; 15 (suppl 2): 101–108.[Medline] [Order article via Infotrieve]

14. Deslypere JP, Verdonck L, Vermeulen A. Fat tissue: a steroid reservoir and site of steroid metabolism. J Clin Endocrinol Metab. 1985; 61: 564–570.[Abstract/Free Full Text]

15. Corbould AM, Judd SJ, Rodgers RJ. Expression of types 1,2 and 3 17 beta-hydroxysteroid dehydrogenase in subcutaneous abdominal and intra-abdominal adipose tissue of women. J Clin Endocrinol Metab. 1998; 83: 187–194.[Abstract/Free Full Text]

16. Corbould AM, Bawden MJ, Lavranos TC, et al. The effect of obesity on the ratio of type 3 17beta-hydroxysteroid dehydrogenase mRNA to cytochrome P450 aromatase mRNA in subcutaneous abdominal and intra-abdominal adipose tissue of women. Int J Obes Relat Metab Disord. 2002; 26: 165–175.[CrossRef][Medline] [Order article via Infotrieve]

17. Motoshima H, Wu X, Sinha MK, et al. Differential regulation of adiponectin secretion from cultured human omental and subcutaneous adipocytes: effects of insulin and rosiglitazone. J Clin Endocrinol Metab. 2002; 87: 5662–5667.[Abstract/Free Full Text]

18. Fisher FM, McTernan PG, Valsamakis G, et al. Differences in adiponectin expression: effect of fat depots and type 2 diabetes status. Horm Metab Res. 2002; 34: 650–654.[CrossRef][Medline] [Order article via Infotrieve]

19. Ducluzeau PH, Cousin P, Malvoisin E, et al. Glucose-to-insulin ratio rather than sex hormone-binding globulin and adiponectin levels is the best predictor of IR in nonobese women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2003; 88: 3626–3631.[Abstract/Free Full Text]

20. Kalish GM, Barrett-Connor E, Laughlin GA, et al. Association of endogenous sex hormones and IR among postmenopausal women: results from the Postmenopausal Estrogen/Progestin Intervention Trial. J Clin Endocrinol Metab. 2003; 88: 1646–1652.[Abstract/Free Full Text]

21. Gavrila A, Chan JL, Yiannakouris N, et al. Plasma adiponectin levels are inversely associated with overall and central fat distribution but are not directly regulated by acute fasting or leptin administration in humans: cross-sectional and interventional studies. J Clin Endocrinol Metab. 2003; 88: 4823–4831.[Abstract/Free Full Text]

22. Homko C, Sivan E, Chen X, et al. Insulin secretion during and after pregnancy in patients with gestational diabetes mellitus. J Clin Endocrinol Metab. 2001; 86: 568–573.[Abstract/Free Full Text]

23. Halleux CM, Takahashi M, Delporte ML, et al. Secretion of adiponectin and regulation of apM1 gene expression in human visceral adipose tissue. Biochem Biophys Res Commun. 2001; 288: 1102–1107.[CrossRef][Medline] [Order article via Infotrieve]

24. Zierath JR, Livingston JN, Thorne A, et al. Regional difference in insulin inhibition of non-esterified fatty acid release from human adipocytes: relation to insulin receptor phosphorylation and intracellular signalling through the insulin receptor substrate-1 pathway. Diabetologia. 1998; 41: 1343–1354.[CrossRef][Medline] [Order article via Infotrieve]

25. Catalano PM, Nizielski SE, Shao J, et al. Downregulated IRS-1 and PPARgamma in obese women with gestational diabetes: relationship to FFA during pregnancy. Am J Physiol Endocrinol Metab. 2002; 282: E522–E533.[Abstract/Free Full Text]

26. Rotter V, Nagaev I, Smith U. Interleukin-6 (IL-6) induces IR in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin-resistant subjects. J Biol Chem. 2003; 278: 45777–45784.[Abstract/Free Full Text]

27. Jansson PA, Pellme F, Hammarstedt A, et al. A novel cellular marker of IR and early atherosclerosis in humans is related to impaired fat cell differentiation and low adiponectin. FASEB J. 2003; 17: 1434–1440.[Abstract/Free Full Text]

28. Gonzalez C, Alonso A, Diaz F, et al. Dose-and time-dependent effect of 17beta-oestradiol on insulin sensitivity in insulin-dependent tissues of rat: implications of IRS-1. J Endocrinol. 2003; 176: 367–379.[Abstract]

29. Yudkin JS, Kumari M, Humphries SE, et al. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis. 2000; 148: 209–214.[CrossRef][Medline] [Order article via Infotrieve]

30. Fried SK, Bunkin DA, Greenberg AS. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab. 1998; 83: 847–850.[Abstract/Free Full Text]

31. Mohamed-Ali V, Goodrick S, Rawesh A, et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab. 1997; 82: 4196–4200.[Abstract/Free Full Text]

32. Xu H, Uysal KT, Becherer JD, et al. Altered tumor necrosis factor-alpha (TNF-alpha) processing in adipocytes and increased expression of transmembrane TNF-alpha in obesity. Diabetes. 2002; 51: 1876–1883.[Abstract/Free Full Text]

33. Sopasakis VR, Sandqvist M, Gustafson B, et al. High local concentrations and effects on differentiation implicate interleukin-6 as a paracrine regulator. Obes Res. 2004; 12: 454–460.[Medline] [Order article via Infotrieve]

34. Bruun JM, Lihn AS, Verdich C, et al. Regulation of adiponectin by adipose tissue–derived cytokines: in vivo and in vitro investigations in humans. Am J Physiol Endocrinol Metab. 2003; 285: E527–E533.[Abstract/Free Full Text]

35. Snijder MB, Visser M, Dekker JM, et al. The prediction of visceral fat by dual-energy X-ray absorptiometry in the elderly: a comparison with computed tomography and anthropometry. Int J Obes Relat Metab Disord. 2002; 26: 984–993.[CrossRef][Medline] [Order article via Infotrieve]

36. Clasey JL, Bouchard C, Teates CD, et al. The use of anthropometric and dual-energy X-ray absorptiometry (DXA) measures to estimate total abdominal and abdominal visceral fat in men and women. Obes Res. 1999; 7: 256–264.[Medline] [Order article via Infotrieve]

37. Ferrara A, Quesenberry CP, Karter AJ, et al. Current use of unopposed estrogen and estrogen plus progestin and the risk of acute myocardial infarction among women with diabetes. Circulation. 2003; 107: 43–48.[Abstract/Free Full Text]

This article has been cited by other articles:

				B. L Heitmann and P. Frederiksen Thigh circumference and risk of heart disease and premature death: prospective cohort study BMJ, September 3, 2009; 339(sep03_2): b3292 - b3292. [Abstract] [Full Text] [PDF]

				T. Christiansen, S. K Paulsen, J. M Bruun, K. Overgaard, S. Ringgaard, S. B Pedersen, V. Positano, and B. Richelsen Comparable reduction of the visceral adipose tissue depot after a diet-induced weight loss with or without aerobic exercise in obese subjects: a 12-week randomized intervention study Eur. J. Endocrinol., May 1, 2009; 160(5): 759 - 767. [Abstract] [Full Text] [PDF]

				M B Snijder, A Flyvbjerg, C D A Stehouwer, J Frystyk, R M A Henry, J C Seidell, R J Heine, and J M Dekker Relationship of adiposity with arterial stiffness as mediated by adiponectin in older men and women: the Hoorn Study Eur. J. Endocrinol., March 1, 2009; 160(3): 387 - 395. [Abstract] [Full Text] [PDF]

				G. R. Hajer, T. W. van Haeften, and F. L.J. Visseren Adipose tissue dysfunction in obesity, diabetes, and vascular diseases Eur. Heart J., December 2, 2008; 29(24): 2959 - 2971. [Abstract] [Full Text] [PDF]

				C. Compher and K. O. Badellino Obesity and Inflammation: Lessons From Bariatric Surgery JPEN J Parenter Enteral Nutr, November 1, 2008; 32(6): 645 - 647. [Abstract] [Full Text] [PDF]

				R H Straub, L B Tanko, C Christiansen, P J Larsen, and D S Jessop Higher physical activity is associated with increased androgens, low interleukin 6 and less aortic calcification in peripheral obese elderly women J. Endocrinol., October 1, 2008; 199(1): 61 - 68. [Abstract] [Full Text] [PDF]

				Y. Tabara, H. Osawa, R. Kawamoto, R. Tachibana-Iimori, M. Yamamoto, J. Nakura, T. Miki, H. Makino, and K. Kohara Reduced High-Molecular-Weight Adiponectin and Elevated High-Sensitivity C-Reactive Protein Are Synergistic Risk Factors for Metabolic Syndrome in a Large-Scale Middle-Aged to Elderly Population: the Shimanami Health Promoting Program Study J. Clin. Endocrinol. Metab., March 1, 2008; 93(3): 715 - 722. [Abstract] [Full Text] [PDF]

				D. Canoy, S. M. Boekholdt, N. Wareham, R. Luben, A. Welch, S. Bingham, I. Buchan, N. Day, and K.-T. Khaw Body Fat Distribution and Risk of Coronary Heart Disease in Men and Women in the European Prospective Investigation Into Cancer and Nutrition in Norfolk Cohort: A Population-Based Prospective Study Circulation, December 18, 2007; 116(25): 2933 - 2943. [Abstract] [Full Text] [PDF]

				A. Tivesten, D. Mellstrom, H. Jutberger, B. Fagerberg, B. Lernfelt, E. Orwoll, M. K. Karlsson, O. Ljunggren, and C. Ohlsson Low Serum Testosterone and High Serum Estradiol Associate With Lower Extremity Peripheral Arterial Disease in Elderly Men: The MrOS Study in Sweden J. Am. Coll. Cardiol., September 11, 2007; 50(11): 1070 - 1076. [Abstract] [Full Text] [PDF]

				T. L. Nielsen, C. Hagen, K. Wraae, K. Brixen, P. H. Petersen, E. Haug, R. Larsen, and M. Andersen Visceral and Subcutaneous Adipose Tissue Assessed by Magnetic Resonance Imaging in Relation to Circulating Androgens, Sex Hormone-Binding Globulin, and Luteinizing Hormone in Young Men J. Clin. Endocrinol. Metab., July 1, 2007; 92(7): 2696 - 2705. [Abstract] [Full Text] [PDF]

				B. Richelsen, S. Tonstad, S. Rossner, S. Toubro, L. Niskanen, S. Madsbad, P. Mustajoki, and A. Rissanen Effect of Orlistat on Weight Regain and Cardiovascular Risk Factors Following a Very-Low-Energy Diet in Abdominally Obese Patients: A 3-year randomized, placebo-controlled study Diabetes Care, January 1, 2007; 30(1): 27 - 32. [Abstract] [Full Text] [PDF]

				S. E Kasim-Karakas, A. Tsodikov, U. Singh, and I. Jialal Responses of inflammatory markers to a low-fat, high-carbohydrate diet: effects of energy intake. Am. J. Clinical Nutrition, April 1, 2006; 83(4): 774 - 779. [Abstract] [Full Text] [PDF]

				C. G. Schalkwijk, N. Chaturvedi, M. T. Schram, J. H. Fuller, C. D. A. Stehouwer, and the EURODIAB Prospective Complications Study Group Adiponectin Is Inversely Associated with Renal Function in Type 1 Diabetic Patients J. Clin. Endocrinol. Metab., January 1, 2006; 91(1): 129 - 135. [Abstract] [Full Text] [PDF]

				L. B. Tanko and C. Christiansen Can the Obesity Paradox Be Explained by the Protective Effects of Peripheral Adiposity? Arch Intern Med, August 8, 2005; 165(15): 1796 - 1797. [Full Text] [PDF]

				L. B. Tanko, Y. Z. Bagger, G. Qin, P. Alexandersen, P. J. Larsen, and C. Christiansen Enlarged Waist Combined With Elevated Triglycerides Is a Strong Predictor of Accelerated Atherogenesis and Related Cardiovascular Mortality in Postmenopausal Women Circulation, April 19, 2005; 111(15): 1883 - 1890. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) All Versions of this Article: 110/15/2246    most recent 01.CIR.0000144470.55149.E5v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tankó, L. B. Articles by Larsen, P. J. Search for Related Content PubMed PubMed Citation Articles by Tankó, L. B. Articles by Larsen, P. J. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB ESTRADIOL Genetics Home Reference Medline Plus Health Information Obesity Related Collections Obesity Pathophysiology Risk Factors Peripheral vascular disease Glucose intolerance Epidemiology